Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

H. Borghaei, L. Paz-Ares, Leora Horn, +23

New England Journal of Medicine

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Dung T. Le, Jennifer N. Uram, Hao Wang, +32

New England Journal of Medicine

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

James Larkin, Vanna Chiarion‐Sileni, René González, +28

New England Journal of Medicine

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Daniel D. Von Hoff, Thomas J. Ervin, Francis P. Arena, +20

New England Journal of Medicine

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Roy S. Herbst, Paul Baas, Dong‐Wan Kim, +16

The Lancet

Pembrolizumab Versus DocetaxelOncologyClinical TrialsImmune Checkpoint InhibitorPharmacotherapy +5

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

Eunice L. Kwak, Yung‐Jue Bang, D. Ross Camidge, +28

New England Journal of Medicine

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

Caroline Robert, L. Thomas, Igor Bondarenko, +21

New England Journal of Medicine

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

Sunil Verma, David Miles, Luca Gianni, +11

New England Journal of Medicine

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles, +28

The Lancet

UrologyMetastatic Urothelial CarcinomaGenitourinary CancerMedicineImmune Checkpoint Inhibitor +6

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

Stephen M. Ansell, Alexander M. Lesokhin, Ivan Borrello, +15

New England Journal of Medicine